Literature DB >> 24598754

The structure of cytomegalovirus immune modulator UL141 highlights structural Ig-fold versatility for receptor binding.

Ivana Nemčovičová1, Dirk M Zajonc1.   

Abstract

Natural killer (NK) cells are critical components of the innate immune system as they rapidly detect and destroy infected cells. To avoid immune recognition and to allow long-term persistence in the host, Human cytomegalovirus (HCMV) has evolved a number of genes to evade or inhibit immune effector pathways. In particular, UL141 can inhibit cell-surface expression of both the NK cell-activating ligand CD155 as well as the TRAIL death receptors (TRAIL-R1 and TRAIL-R2). The crystal structure of unliganded HCMV UL141 refined to 3.25 Å resolution allowed analysis of its head-to-tail dimerization interface. A `dimerization-deficient' mutant of UL141 (ddUL141) was further designed, which retained the ability to bind to TRAIL-R2 or CD155 while losing the ability to cross-link two receptor monomers. Structural comparison of unliganded UL141 with UL141 bound to TRAIL-R2 further identified a mobile loop that makes intimate contacts with TRAIL-R2 upon receptor engagement. Superposition of the Ig-like domain of UL141 on the CD155 ligand T-cell immunoreceptor with Ig and ITIM domains (TIGIT) revealed that UL141 can potentially engage CD155 similar to TIGIT by using the C'C'' and GF loops. Further mutations in the TIGIT binding site of CD155 (Q63R and F128R) abrogated UL141 binding, suggesting that the Ig-like domain of UL141 is a viral mimic of TIGIT, as it targets the same binding site on CD155 using similar `lock-and-key' interactions. Sequence alignment of the UL141 gene and its orthologues also showed conservation in this highly hydrophobic (L/A)X6G `lock' motif for CD155 binding as well as conservation of the TRAIL-R2 binding patches, suggesting that these host-receptor interactions are evolutionary conserved.

Entities:  

Keywords:  CD155; TRAIL-R2; UL141; cytomegalovirus; immune modulators

Mesh:

Substances:

Year:  2014        PMID: 24598754      PMCID: PMC3949518          DOI: 10.1107/S1399004713033750

Source DB:  PubMed          Journal:  Acta Crystallogr D Biol Crystallogr        ISSN: 0907-4449


  60 in total

1.  SFCHECK: a unified set of procedures for evaluating the quality of macromolecular structure-factor data and their agreement with the atomic model.

Authors:  A A Vaguine; J Richelle; S J Wodak
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1999-01-01

2.  ProMate: a structure based prediction program to identify the location of protein-protein binding sites.

Authors:  Hani Neuvirth; Ran Raz; Gideon Schreiber
Journal:  J Mol Biol       Date:  2004-04-16       Impact factor: 5.469

3.  Structure of TIGIT immunoreceptor bound to poliovirus receptor reveals a cell-cell adhesion and signaling mechanism that requires cis-trans receptor clustering.

Authors:  Katharina F Stengel; Kristin Harden-Bowles; Xin Yu; Lionel Rouge; Jianping Yin; Laëtitia Comps-Agrar; Christian Wiesmann; J Fernando Bazan; Dan L Eaton; Jane L Grogan
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-15       Impact factor: 11.205

4.  iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM.

Authors:  T Geoff G Battye; Luke Kontogiannis; Owen Johnson; Harold R Powell; Andrew G W Leslie
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2011-03-18

5.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

Review 6.  Scaling and assessment of data quality.

Authors:  Philip Evans
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2005-12-14

7.  MolProbity: all-atom structure validation for macromolecular crystallography.

Authors:  Vincent B Chen; W Bryan Arendall; Jeffrey J Headd; Daniel A Keedy; Robert M Immormino; Gary J Kapral; Laura W Murray; Jane S Richardson; David C Richardson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-12-21

8.  Human cytomegalovirus glycoprotein UL141 targets the TRAIL death receptors to thwart host innate antiviral defenses.

Authors:  Wendell Smith; Peter Tomasec; Rebecca Aicheler; Andrea Loewendorf; Ivana Nemčovičová; Eddie C Y Wang; Richard J Stanton; Matt Macauley; Paula Norris; Laure Willen; Eva Ruckova; Akio Nomoto; Pascal Schneider; Gabriele Hahn; Dirk M Zajonc; Carl F Ware; Gavin W G Wilkinson; Chris A Benedict
Journal:  Cell Host Microbe       Date:  2013-03-13       Impact factor: 21.023

9.  Structure of human cytomegalovirus UL141 binding to TRAIL-R2 reveals novel, non-canonical death receptor interactions.

Authors:  Ivana Nemčovičová; Chris A Benedict; Dirk M Zajonc
Journal:  PLoS Pathog       Date:  2013-03-21       Impact factor: 6.823

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  3 in total

1.  The structure of the cytomegalovirus-encoded m04 glycoprotein, a prototypical member of the m02 family of immunoevasins.

Authors:  Richard Berry; Julian P Vivian; Felix A Deuss; Gautham R Balaji; Philippa M Saunders; Jie Lin; Dene R Littler; Andrew G Brooks; Jamie Rossjohn
Journal:  J Biol Chem       Date:  2014-06-30       Impact factor: 5.157

2.  Crystal structure of murine 4-1BB and its interaction with 4-1BBL support a role for galectin-9 in 4-1BB signaling.

Authors:  Aruna Bitra; Tzanko Doukov; Jing Wang; Gaelle Picarda; Chris A Benedict; Michael Croft; Dirk M Zajonc
Journal:  J Biol Chem       Date:  2017-12-14       Impact factor: 5.157

3.  Plasma membrane profiling defines an expanded class of cell surface proteins selectively targeted for degradation by HCMV US2 in cooperation with UL141.

Authors:  Jye-Lin Hsu; Dick J H van den Boomen; Peter Tomasec; Michael P Weekes; Robin Antrobus; Richard J Stanton; Eva Ruckova; Daniel Sugrue; Gavin S Wilkie; Andrew J Davison; Gavin W G Wilkinson; Paul J Lehner
Journal:  PLoS Pathog       Date:  2015-04-14       Impact factor: 7.464

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.